Tamoxifen-Phospholipid Complex May Alleviate TMX Toxicity
(HealthDay News) — Administration of a tamoxifen-phospholipid complex (TMX-PLC) is associated with improvement in TMX-induced hepatotoxicity in rats, according to an experimental study published in the September issue of the Journal of Pharmacy and Pharmacology.
Sunil K. Jena, from the National Institute of Pharmaceutical Education and Research in Mohali, India, and colleagues examined the ameliorative effect of phospholipid against TMX-induced hepatotoxicity in female Sprague-Dawley rats. Fifteen rats were divided into three groups and received either only standard diet and distilled water (normal), TMX (control), or TMX-PLC for 28 days.
The researchers observed a significant amelioration in TMX-induced hepatotoxicity with TMX-PLC, which diminished toxicity markers such as lipid peroxidation, aspartate transaminase, and alanine transaminase. Furthermore, there was an increase in antioxidant enzyme activity with TMX-PLC administration. The hepatoprotective effect of phospholipid was confirmed in histological findings.
"Data of the present study suggests that phospholipid may prove as a useful component of combination therapy in cancer patients under the TMX treatment regimen," the authors write.